Shares of Novo Nordisk A/S (NVO) plummeted 5.03% during Wednesday's trading session, following news that the company is under investigation by Spain's ministry of health. The probe concerns the pharmaceutical giant's website communications about its weight-loss drug, which could potentially violate advertising regulations for prescription medications.
According to a statement from the Spanish government body, the communications on Novo Nordisk's website "could be considered as covert advertising of prescription drugs, which is prohibited by current legislation." The ministry has sent a request for clarification to the company regarding its "Obesity Without Filters" online awareness campaign, which appeared to have been taken down following the investigation announcement.
This development comes at a sensitive time for Novo Nordisk, as the company faces increasing competition in the growing weight-loss drug market. The investigation adds to previous criticism the company has faced in the UK over its promotional practices. Last year, Novo Nordisk was temporarily suspended from the UK's pharmaceutical industry association for breaching the country's code of practice for drugmakers, though its membership has since been restored.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。